A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Trial Profile

A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed
Phase of Trial: Phase III

Latest Information Update: 14 May 2018

At a glance

  • Drugs Sapacitabine (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SEAMLESS
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 14 May 2018 According to a Cyclacel Pharmaceuticals media release, the company is planning to conduct regulatory authority meetings in 2018.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 According to a Cyclacel Pharmaceuticals media release, the company is planning to discuss the data from this trial with European and US regulatory authorities and intends to provide updates as appropriate.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top